Moderna recently issued a press release to investors reporting that the TeenCOVE study met its primary immunogenicity endpoint, that is the results indicate that the…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.